open access

Vol 64, No 5 (2013)
Original papers
Published online: 2013-11-01
Submitted: 2013-11-04
Accepted: 2013-11-04
Get Citation

Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland — subgroup data from a randomised multinational trial GWAA

Beata Matyjaszek-Matuszek, Monika Lenart-Lipińska, Dorota Rogalska, Andrzej Nowakowski, GWAA Polish Study Group
DOI: 10.5603/EP.2013.0021
·
Endokrynologia Polska 2013;64(5):375-382.

open access

Vol 64, No 5 (2013)
Original papers
Published online: 2013-11-01
Submitted: 2013-11-04
Accepted: 2013-11-04

Abstract

Introduction: We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes
sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.

Material and methods: In Poland, 80 patients (HbA1c 7–10%, BMI 25–45 kg/m2) were randomised to exenatide 10 μg BID (n = 40) or insulin
glargine once daily (n = 40). We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).

Results: Mean (SD) baseline HbA1c was 7.9% (0.86) for exenatide and 7.8% (1.02) for insulin glargine. At Week 26, LS mean (SEM) HbA1c
decreased in both groups (exenatide –0.72% [0.12]; glargine –0.64% [0.12]), as did fasting glucose. Postprandial glucose excursions after
breakfast and dinner were smaller in patients treated with exenatide. LS mean (SEM) body weight decreased by –1.9 (0.48) kg with exenatide
and increased by 1.6 (0.48) kg with glargine (group difference [95%CI]: –3.5 kg [–4.9 to –2.2]). Hypoglycaemia was low in both
groups; nocturnal hypoglycaemia was reported for three v. seven patients (three v. 24 episodes) in the exenatide and glargine groups,
respectively. Adverse events were more common with exenatide (nausea n = 22 v. n = 1, vomiting n = 5 v. n = 0, headache n = 8 v. n = 2).

Conclusion: This exploratory analysis confirms that findings from the global study apply to patients treated with exenatide BID and
glargine in Poland, showing that exenatide BID was as effective as insulin glargine. Data suggested that changes in HbA1c were similar,
with fasting glucose changes greater in the glargine group and postprandial changes greater in the exenatide BID group. Exenatide BID
was associated with weight reduction, less nocturnal hypoglycaemia, but more gastrointestinal events compared to glargine.

(Endokrynol Pol 2013; 64 (5): 375–382)

Abstract

Introduction: We explored the safety and efficacy of exenatide BID v. insulin glargine in a subgroup of Polish patients with type 2 diabetes
sub-optimally controlled with metformin plus a sulfonylurea, participating in a 26-week randomised, controlled open-label trial.

Material and methods: In Poland, 80 patients (HbA1c 7–10%, BMI 25–45 kg/m2) were randomised to exenatide 10 μg BID (n = 40) or insulin
glargine once daily (n = 40). We present exploratory analyses on HbA1c, glucose profiles, body weight, hypoglycaemia and adverse events (AEs).

Results: Mean (SD) baseline HbA1c was 7.9% (0.86) for exenatide and 7.8% (1.02) for insulin glargine. At Week 26, LS mean (SEM) HbA1c
decreased in both groups (exenatide –0.72% [0.12]; glargine –0.64% [0.12]), as did fasting glucose. Postprandial glucose excursions after
breakfast and dinner were smaller in patients treated with exenatide. LS mean (SEM) body weight decreased by –1.9 (0.48) kg with exenatide
and increased by 1.6 (0.48) kg with glargine (group difference [95%CI]: –3.5 kg [–4.9 to –2.2]). Hypoglycaemia was low in both
groups; nocturnal hypoglycaemia was reported for three v. seven patients (three v. 24 episodes) in the exenatide and glargine groups,
respectively. Adverse events were more common with exenatide (nausea n = 22 v. n = 1, vomiting n = 5 v. n = 0, headache n = 8 v. n = 2).

Conclusion: This exploratory analysis confirms that findings from the global study apply to patients treated with exenatide BID and
glargine in Poland, showing that exenatide BID was as effective as insulin glargine. Data suggested that changes in HbA1c were similar,
with fasting glucose changes greater in the glargine group and postprandial changes greater in the exenatide BID group. Exenatide BID
was associated with weight reduction, less nocturnal hypoglycaemia, but more gastrointestinal events compared to glargine.

(Endokrynol Pol 2013; 64 (5): 375–382)

Full Text:

View HTML
Get Citation

Keywords

type 2 diabetes mellitus; GLP-1 agonist; exenatide; insulin glargine

About this article
Title

Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland — subgroup data from a randomised multinational trial GWAA

Journal

Endokrynologia Polska

Issue

Vol 64, No 5 (2013)

Pages

375-382

Published online

2013-11-01

DOI

10.5603/EP.2013.0021

Bibliographic record

Endokrynologia Polska 2013;64(5):375-382.

Keywords

type 2 diabetes mellitus
GLP-1 agonist
exenatide
insulin glargine

Authors

Beata Matyjaszek-Matuszek
Monika Lenart-Lipińska
Dorota Rogalska
Andrzej Nowakowski
GWAA Polish Study Group

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl